Not long ago, infiltrations and extravasations lived in the shadows—quiet conversations at the nurses’ station, chart notes carefully worded, incidents minimized or chalked up to “one of those things.” Today, many hospitals have PIVIE (Peripheral IV Infiltration and Extravasation) committees, updated policies, and readily available remedies like antidotes administration. And yet, despite all this attention, most hospitals remain reactive.
With no governing body mandating standardized reporting, tracking, or prevention protocols, PIVIEs are still largely managed after patient harm has occurred—through antidotes, wound care consults, or, in severe cases, surgical intervention. The injury happens first. The response comes later.
The uncomfortable truth is this: extravasations are hospital-acquired events. They place patients, clinicians, and institutions at risk. And while PIVIEs will happen—even in the most skilled hands—the severe patient harm that can follow does not have to.
Where Do PIVIEs “Happen”? Everywhere.
Ask most clinicians where the highest risk for extravasations live, and you’ll hear a familiar answer: oncology and critical care.
That assumption makes sense. These units routinely administer known vesicants—chemotherapy agents and vasopressors—where even small amounts of fluid escaping the vein can cause devastating harm. Because the risk is well understood, the vigilance is high.
But here’s the part we don’t talk about enough: PIVIEs are not confined to these units. They occur anywhere peripheral IVs are used—which means every unit in every hospital. Medical–surgical floors. Labor and delivery. Emergency departments. Observation units. And increasingly, these areas are administering medications that can cause tissue injury just as severe as traditional vesicants.
The Overlooked Vesicants Hiding in Plain Sight
While chemotherapy and vasopressors dominate extravasation education, they are not the most frequently infused medications hospital wide. Many patients outside of ICU and oncology now receive IV therapies with significant extravasation potential, including:
- Potassium chloride
- Calcium salts
- High-concentration dextrose
- Promethazine
- Certain antibiotics
- Sodium bicarbonate
As patient acuity rises across the hospital, these infusions are no longer rare events on general units—they’re becoming routine. And because they don’t carry the same “high-risk” label, the danger is often underestimated.
That underestimation comes at a cost.
Injuries that occur outside of oncology and critical care are more likely to be missed early, underreported, or recognized only after visible tissue damage has already occurred—when options are limited, and outcomes are worse.
Antidotes Exist—but They Are Not a Strategy
Yes, antidotes are available. Many hospitals maintain extravasation management charts and algorithms. Pharmacy teams are increasingly familiar with agents like hyaluronidase and other treatment agents—and many are reporting a rise in demand for these antidotes. That rise should give us pause.
Antidotes are reactive treatments. They are most effective when a PIVIE is identified early—before swelling, blanching, blistering, or necrosis to appear. Once tissue injury is established, antidotes can mitigate damage, but they cannot undo it.
Relying on antidotes is not prevention. It is damage control.
Sample scenarios for educational purposes (follow your hospital’s approved protocols).
From Reaction to Prevention: The Case for Early Detection
If PIVIEs are inevitable, then early detection becomes the differentiator between a minor event and a life-altering injury.
This is where hospitals must shift from awareness to action—from reactive treatment to proactive monitoring. IV surveillance technology that monitors early signs of infiltration and extravasation offer clinicians a chance to intervene before harm occurs, rather than solely treating it afterward.
For clinicians, this isn’t about blame or perfection. It’s about support.
For patients, it’s about safety.
For hospitals, it’s about reducing preventable harm.
PIVIEs don’t just happen in oncology and critical care. They happen wherever IV therapy is delivered. The question is no longer if they’ll occur—but whether we’ll catch them in time.